(IN BRIEF) Sanofi's experimental CD40L antibody, frexalimab, demonstrates encouraging results in a 48-week phase 2 study for relapsing multiple sclerosis…
(IN BRIEF) Evotec SE announces the appointment of Aurélie Dalbiez as their new Chief People Officer (CPO), effective June 15,…
(IN BRIEF) Novartis revealed promising data from the ALITHIOS open-label extension study, highlighting the enduring effectiveness of Kesimpta® (ofatumumab) in…
(IN BRIEF) AstraZeneca's IMPACT CKD model predicts a significant increase in chronic kidney disease (CKD) across eight countries, with up…
(IN BRIEF) Bosch and Randox Laboratories Ltd. have forged a strategic partnership aimed at transforming molecular diagnostics with a focus…
(IN BRIEF) The European Bank for Reconstruction and Development (EBRD) has provided a €22 million loan to Ukrainian pharmaceutical giant…
(IN BRIEF) WACKER's mRNA competence center in Halle is gearing up to produce an active ingredient for combatting acute respiratory…
(IN BRIEF) AstraZeneca announces positive outcomes from the ADRIATIC Phase III trial, revealing that its immunotherapy drug Imfinzi (durvalumab) demonstrated…
(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for…
(IN BRIEF) AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been acknowledged by the US…